compounded semaglutide crackdown news october 2025 FDA is moving to restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified Eli Lilly telehealth partners continue

Evidence-based lifestyle interventionsincluding structured dietary advice, physical activity programmes, and psychological supportshould be explored as first-line approaches

Prices typically range from $179-299 per month, making it the most cost-effective GLP-1 option available

The effectiveness of drugs like Novo Nordisk's Wegovy and Saxenda, which are approved for weight loss, as well as the diabetes drug Ozempic has created sky-high demand while off-label use of the drugs also has driven supply challenges in recent months

Approximately 5-10% of patients experience prolonged symptoms that don't follow the typical resolution curve

(12) These challenges lengthen hospital stays, increase the need for readmissions or revision procedures, and impair long-term functional outcomes